Philip­pine health of­fi­cials or­der Sanofi to halt Deng­vax­ia sales as con­tro­ver­sy over health threat swells

Philip­pine health of­fi­cials have or­dered Sanofi to jerk its dengue vac­cine off the mar­ket as the con­tro­ver­sy over the health threat it pos­es to chil­dren con­tin­ues to roil the coun­try.

The Philip­pines was the first coun­try to launch a ma­jor vac­ci­na­tion cam­paign with Deng­vax­ia, the world’s first dengue vac­cine. But last week Sanofi con­ced­ed some­thing that two ex­pert groups had con­clud­ed in­de­pen­dent­ly just as the coun­try was rolling out its $70 mil­lion ef­fort ear­ly last year. The vac­cine, giv­en to any­one who had not al­ready been in­fect­ed, left peo­ple vul­ner­a­ble to se­vere, life-threat­en­ing dengue in the event they were sub­se­quent­ly in­fect­ed by wild type dengue.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.